Resolution of secondary hemophagocytic lymphohistiocytosis after treatment with the JAK1/2 inhibitor ruxolitinib.

Goldsmith, Scott R; Saif Ur Rehman, Sana; Shirai, Cara L; Vij, Kiran; DiPersio, John F

Goldsmith, Scott R; Saif Ur Rehman, Sana; Shirai, Cara L; Vij, Kiran; DiPersio, John F.

Afiliação

Goldsmith SR; Division of Oncology, Department of Medicine.
Saif Ur Rehman S; Division of Hematology, Department of Medicine, and.
Shirai CL; Division of Hematology, Department of Medicine, and.
Vij K; Department of Pathology and Immunology, Washington University School of Medicine, St. Louis, MO.
DiPersio JF; Division of Oncology, Department of Medicine.

Blood Adv ; 3(23): 4131-4135, 2019 12 10.

Article em En | MEDLINE | ID: mdl-31821455

Assuntos

Janus Quinases/antagonistas & inibidores; Linfo-Histiocitose Hemofagocítica/induzido quimicamente; Pirazóis/efeitos adversos; Humanos; Nitrilas; Pirimidinas

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Pirazóis / Linfo-Histiocitose Hemofagocítica / Janus Quinases Limite: Humans Idioma: En Ano de publicação: 2019 Tipo de documento: Article

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google